Trinity recently convened its leadership team to examine the scale of the industry’s current commercialization challenges and stress test the solutions we are bringing to clients. Our senior leadership articulated the six most material issues facing biopharma today and created space for leaders to share how they are responding in active engagements.
There is a growing paradox in life sciences commercialization: more data and more research than ever, yet many critical decisions still rely on static decks, siloed databases, and one time studies that go stale almost immediately. Commercial, medical, and market access teams are working harder than ever—often with tools that were never designed for the pace and complexity of today’s markets.
Most commercial life sciences organizations have invested heavily in data. They have lakehouses, harmonized data feeds, and dashboard environments like Power BI, Tableau, and Snowflake that teams rely on daily. These tools already carry semantic models: metric definitions, schema relationships, and governed sources. The analytics infrastructure is real. Yet when they try to build AI on top of it, they hit the same wall: the AI doesn’t understand their business.
Market access teams routinely make high-stakes decisions with incomplete information and compressed timelines. Primary market research remains the gold standard, but in-depth interviews with payers are expensive, logistically complex, and difficult to repeat iteratively as strategy and data evolves. The result is that value messaging frameworks, Target Product Profile (TPP) assumptions, and pricing strategies often have limited payer testing before they meet real payers.
China is evolving beyond a single public reimbursement model toward a layered access system that combines national coverage, commercial funding, and early access programs. In 2025, these changes began to reshape how manufacturers think about pricing, evidence, and launch sequencing…
Latin American and MENA markets have long faced the challenge of balancing constrained public budgets with rising demand for newer therapies. In 2025, governments in these regions took concrete steps to modernize pricing rules, raise evidence expectations, expand partnership models,…
Across Europe, 2025 accelerated a shift from sequential regulatory and access steps to more connected process through the Joint Clinical Assessment. Regulatory approvals, and clinical portion of HTA evaluation are now more tightly linked, which has the potential to bring…
Globally, 2025 marked a shift from debating drug pricing policy to implementing it. Pricing pressure intensified, evidence expectations rose, and long-standing access models began to change amid political and fiscal realities. In Trinity’s webinar “Around the World in Market Access…
Interventional cardiology continues to advance toward precision-based care, where treatment strategies are matched to patient characteristics and real-world outcomes guide decision-making. Coming out of TCT 2025, one of the leading interventional cardiology conferences, Trinity sees four trends shaping the next…
The Most Favored Nation (MFN) pricing policy is once again under consideration in the U.S. First put forward in a 2020 Executive Order (EO) by the Trump Administration, the 2025 MFN policy aims to eliminate global free riding by aligning…